Key Features

30mg Reta per pen
Each pen contains 30mg in a 3ml solution.

Pre-filled 3ml pen format
No vial mixing or reconstitution required.

Click-based measuring system
Designed for simple, consistent measurement during research use.

Premium lab sourcing
Sourced from a specialist German laboratory.

Includes disposable needle tips
Packaged as a complete research pen kit.

Product Details

Product name: RETLIRA 30
Compound: Reta
Strength: 30mg
Volume: 3ml
Format: Pre-filled research pen
Pack contents: 1 pre-filled pen with disposable needle tips
Use: Research purposes only

Important Notice

This product is supplied strictly for research purposes only. It is not registered as a medicine, is not approved as a treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or animal consumption. Use only in accordance with applicable research and laboratory guidelines.

Research Reference & Study Protocol Notes

RETLIRA 30 contains 30mg of R3t@trutide (LY3437943) in a 3ml pre-filled research format.

R3t@trutide is an investigational triple-receptor agonist being studied for activity involving GLP-1, GIP and glucagon receptor pathways.

Research involving LY3437943 has investigated metabolic signalling, glucose regulation, energy metabolism, body-weight outcomes and related cardiometabolic research areas.

This product page does not provide a human-use dosing or administration protocol. Researchers should refer to peer-reviewed literature, registered clinical trials, institutional research procedures and applicable regulatory requirements when designing or conducting research.

Primary research reference:

Jastreboff AM, et al. Triple–Hormone-Receptor Agonist R3t@trutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. DOI: 10.1056/NEJMoa2301972.

Research use only.

Frequently Asked Questions — RETLIRA 30

1. What is RETLIRA 30?

RETLIRA 30 is a research-focused peptide product containing 30mg of R3t@trutide in a 3ml pre-filled pen format. It is supplied for laboratory and scientific research purposes.

2. What is R3t@trutide?

R3t@trutide is a synthetic peptide that has been investigated for its activity across multiple receptor pathways, including GLP-1, GIP and glucagon receptor signalling. It is an area of ongoing metabolic and peptide research.

3. What is RETLIRA 30 being researched for?

Research involving R3t@trutide has examined areas including metabolic signalling, glucose metabolism, energy metabolism and multi-receptor agonism. Research findings should always be evaluated within the context of the relevant scientific literature.

4. How much R3t@trutide is in RETLIRA 30?

RETLIRA 30 contains 30mg of R3t@trutide in a 3ml pre-filled research pen format, as specified on the product listing.

5. What does multi-receptor agonism mean?

Multi-receptor agonism refers to a compound interacting with more than one receptor pathway. R3t@trutide has attracted research interest because of its activity involving GLP-1, GIP and glucagon receptor pathways.

6. What are GLP-1, GIP and glucagon receptors?

GLP-1, GIP and glucagon are signalling pathways involved in different aspects of metabolic physiology. Researchers investigate these pathways to better understand processes such as glucose regulation, energy metabolism and appetite-related signalling.

7. Is RETLIRA 30 an approved medicine?

RETLIRA 30 is supplied by Health-Tech as a research-focused product and should not be represented as an approved medicine or treatment. Researchers should consult applicable regulatory requirements and scientific literature before conducting research.

8. What research format is RETLIRA 30 supplied in?

RETLIRA 30 is supplied in a 30mg / 3ml pre-filled pen format. The product format and specifications are provided for identification and laboratory research purposes.

9. Where can I find research information about R3t@trutide?

Researchers should refer to peer-reviewed scientific publications, registered studies and reputable scientific databases when evaluating R3t@trutide. Health-Tech's research information is intended as a general reference and should not replace primary scientific literature.

10. Does Health-Tech provide a human-use protocol for RETLIRA 30?

No. Health-Tech does not provide a human-use dosing or administration protocol for this research product. Researchers should follow appropriate institutional procedures, laboratory protocols, safety requirements and applicable regulations when conducting scientific research.

Research Disclaimer

RETLIRA 30 is presented for laboratory and scientific research purposes only. The information provided on this page is educational and research-focused and does not constitute medical advice, treatment guidance or a recommendation for human use.

Research Reference & Study Information

R3t@trutide (LY3437943) Research Overview

R3t@trutide, also known as LY3437943, is an investigational peptide being studied for its activity across three hormone-receptor pathways: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. This multi-receptor activity is a major area of interest in metabolic research.

A Phase 2 randomized, double-blind, placebo-controlled study published in the New England Journal of Medicine evaluated R3t@trutide in adults with obesity over 48 weeks. The study examined body-weight change, metabolic measures and safety outcomes and provided clinical evidence supporting continued investigation of the compound.

Current Clinical Research

R3t@trutide has progressed into Phase 3 clinical research. Registered studies have investigated the compound across several research areas, including obesity and overweight, cardiovascular disease, obstructive sleep apnea and knee osteoarthritis.

The TRIUMPH-1 Phase 3 programme investigated R3t@trutide in participants with obesity or overweight, including research populations involving knee osteoarthritis and obstructive sleep apnea.

Key Research Areas

Current and published R3t@trutide research includes investigation of:

• Multi-receptor agonism involving GIP, GLP-1 and glucagon receptors
• Metabolic and energy-regulation pathways
• Body-weight and body-composition outcomes
• Glucose and cardiometabolic measures
• Long-term safety and tolerability
• Comparison with other investigational or established metabolic therapies
• Maintenance of weight reduction

Primary Research References

1. Jastreboff AM, et al. — Triple–Hormone-Receptor Agonist R3t@trutide for Obesity: A Phase 2 Trial

New England Journal of Medicine, 2023;389:514–526.
DOI: 10.1056/NEJMoa2301972

This randomized Phase 2 study evaluated R3t@trutide in adults with obesity and assessed efficacy and safety outcomes over 48 weeks. The published study identified R3t@trutide (LY3437943) as an agonist of the GIP, GLP-1 and glucagon receptors.

Research reference:
NEJM — Phase 2 R3t@trutide Study

2. TRIUMPH-1 — Phase 3 R3t@trutide Research Programme

ClinicalTrials.gov: NCT05929066

The TRIUMPH-1 programme investigated the efficacy and safety of LY3437943 in participants with obesity or overweight, including research populations involving knee osteoarthritis and obstructive sleep apnea.

Research reference:
TRIUMPH-1 Clinical Trial Information

Research Status

R3t@trutide remains an investigational compound and is not presented by Health-Tech as an approved medicine or treatment. Clinical research findings should be interpreted according to the design, population, endpoints and limitations of each individual study.

Researchers should consult the original publications, registered clinical-trial records and applicable institutional requirements when evaluating R3t@trutide research.

Research Notice

RETLIRA 30 is presented for laboratory and scientific research purposes only. Information on this page is educational and research-focused and does not constitute medical advice, treatment guidance or a human-use protocol.